Jiuzhitang has released its 2026 half-year performance forecast, expecting attributable net profit of 241 million to 264 million yuan, a year-on-year increase of 67.63% to 83.63%. The company stated that Harbin Jixianglong Biotechnology was consolidated into the financial statements in November 2025 and has performed well during the reporting period, driving net profit growth. The structural optimization and marketing system reform of the original main business segments are gradually showing results, with sales volumes of most products increasing. At the same time, deeper lean management and cost control have improved operational efficiency, leading to overall business performance growth.
Jiuzhitang Co LtdCompany expects net profit to rise 67.63%-83.63% year-on-year, driven by consolidation of subsidiary and improved operations.
Subsidiary performed well during the reporting period, contributing to net profit growth.